Zealand Pharma A/S (OTCMKTS:ZLDPF) Sees Unusually-High Trading Volume – Still a Buy?

Zealand Pharma A/S (OTCMKTS:ZLDPF) shares saw an uptick in trading volume on Tuesday . 8,755 shares changed hands during mid-day trading, an increase of 224% from the previous session’s volume of 2,699 shares.The stock last traded at $46.3750 and had previously closed at $47.30.

Analyst Upgrades and Downgrades

ZLDPF has been the subject of a number of research reports. Jefferies Financial Group cut shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. Wells Fargo & Company reaffirmed an “overweight” rating on shares of Zealand Pharma A/S in a report on Thursday, August 13th. Berenberg Bank lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Wednesday, June 17th. Wolfe Research downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Thursday, June 11th. Finally, Zacks Research cut Zealand Pharma A/S from a “hold” rating to a “strong sell” rating in a report on Thursday, August 13th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold”.

Zealand Pharma A/S Price Performance

The company has a debt-to-equity ratio of 0.02, a quick ratio of 37.17 and a current ratio of 37.17. The stock has a market capitalization of $3.32 billion, a PE ratio of 7.69 and a beta of 0.89. The company’s fifty day simple moving average is $47.53 and its two-hundred day simple moving average is $47.29.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark?based biopharmaceutical company specializing in the discovery, design and development of peptide?based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.